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Purpose: To investigate associations between serum thyroid stimulating hormone (TSH) receptor antibody 
(TRAb) levels and Graves’ orbitopathy (GO) activity/severity in chronic-stage GO and compare the perfor-
mance of two newly-developed TRAb assays (third-generation TSH-binding inhibition immunoglobulin [TBII] 
assay versus Mc4 thyroid-stimulating immunoglobulin [TSI] bioassay).
Methods: This study is a retrospective review of medical charts and blood tests from Korean GO patients who 
first visited the departments of ophthalmology and endocrinology, Yonsei University College of Medicine from 
January 2008 to December 2011, were diagnosed with GO and Graves’ hyperthyroidism, and were followed 
up for ≥18 months. Third-generation M22-TBII and Mc4-TSI assays were performed in the chronic-inactive GO 
patients in whom euthyroidism status was restored. Patients’ GO activity/severity clinical activity scores (CAS), 
and modified NOSPECS scores were examined for a correlation with TRAb assays.
Results: Fifty patients (mean age, 41.3 years; 41 females) were analyzed. The mean duration of Graves’ hy-
perthyroidism symptom was 63 months (range, 18 to 401 months) and that of GO was 46 months (range, 18 
to 240 months). All patients had been treated previously with anti-thyroid drugs for a median period of 52.3 
months, and two patients underwent either radioiodine therapy or total thyroidectomy. Mean CAS and NO-
SPECS scores were 0.5 ± 0.9 (standard deviation) and 4.8 ± 3.1, respectively. Mean M22-TBII and Mc4-TSI 
values were 7.5 ± 10.2 IL/L and 325.9 ± 210.1 specimen-to-reference control ratio. TSI was significantly cor-
related with NOSPECS score (R = 0.479, p < 0.001); however, TBII was not associated with NOSPECS score 
(p = 0.097). Neither TSI nor TBII correlated with CAS (p > 0.05), because GO inflammatory activity subsided 
in the chronic stages of GO.
Conclusions: In chronic-inactive GO after euthyroid restoration, GO activity score did not associate with se-
rum levels of TRAb or TBII. However, levels of the functional antibody Mc4-TSI did correlate with GO severity. 
Therefore, the TSI bioassay is a clinically relevant measure of disease severity even in chronic inactive GO.
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Graves’ orbitopathy (GO) is a component of autoimmune 
Graves’ hyperthyroidism, in which thyroid stimulating 
hormone (TSH) receptor antibody (TRAb) stimulates orbit-
al and periorbital tissues [1]. The natural history of GO is 
not well understood. It is generally thought that GO has an 
inflammatory, active phase that subsides after 1 to 2 years. 
The average active inflammatory phase duration is approx-
imately 18 months (range, 3 to 36 months) [2]. After the in-
flammation subsides, patients may suffer permanent struc-
tural changes around the eyes that require surgical repair.
Currently, there are two established assays to measure 
TRAb: the competitive TSH-binding inhibition immuno-
globulin (TBII) assay and the functional thyroid-stimulat-
ing immunoglobulin (TSI) bioassay [3,4]. The TBII assay 
utilizes the ability of TRAb to inhibit the binding of radio-
labeled TSH to TSH-receptors. The newly-developed, 
third-generation TBII assay measures the inhibition in the 
binding of a labelled monoclonal antibody clone M22 to 
the TSH-receptor rather than the traditional radiolabeled 
TSH-TSH receptor binding [4,5]. This assay enhanced the 
sensitivity and specificity of earlier assays using radiolabe-
led TSH [6-8]. The TSI bioassay measures cyclic adenosine 
monophosphate production af ter TRAb binds to the 
TSH-receptor, thus enabling identification of functional 
TRAb [9,10]. The development of the Mc4-CHO cell line 
simplified the cell culture protocols for the TRAb bio-
assays. The Mc4-CHO TSI bioassay has superior diagnos-
tic potential for differentiating Graves’ disease (GD) from 
painless thyroiditis [11].
Recently, several reports have focused on the relevance 
of TRAb, especially TSI, in untreated early stage GO [12]. 
Ponto et al. [13] reported that TSI levels correlated with 
disease activity (R = 0.89) and severity (R = 0.81) in 
untreated GO. Lytton et al. [12] showed a similar correla-
tion between TSI and GO activity/severity. In previous 
studies we investigated whether serum TRAb in newly-
diagnosed, untreated GO patients were predictive of the 
disease course beyond the f irst year after the initial 
diagnosis [14]. The results showed that patients with higher 
initial TRAb levels had a greater risk of severe disease 
outcomes. Likewise, we hypothesized that serum TRAb 
levels could provide important prognostic information to 
clinicians regarding early stage GO patients [14].
To the best of our knowledge, no prior reports of TRAb 
levels in chronic stage GO patients have been published. 
Chronic stage GO frequently imposes severe psychological, 
social, and economic burdens on patients because patients 
often experience substantial facial disfigurement including 
proptosis, puffy eyelids, and strabismus [1,15,16]. Although 
GO usually spontaneously resolves, patients often show 
heterogeneous clinical courses with complications such as 
restrictive strabismus and severe proptosis. We observed 
that patients who were current heavy smokers or of old age 
often exhibited high serum TSI levels even after prolonged 
anti-thyroid drug (ATD) treatment. TRAb level, TSI and 
TBII was usually high during the early disease period, and 
decreased gradually during ATD treatment. TBII typically 
decreased after a few months of ATD treatment, however, 
TSI levels generally remained high, especially in patients 
with complicated GO. 
In the present study, we investigated the associations be-
tween serum TRAb levels and GO activity/severity in 
chronic-stage GO and compared the performance of two 
newly-developed TRAb assays: the third-generation TBII 
assay and the Mc4-TSI bioassay. 
Materials and Methods
Patients
A retrospective review was conducted of the medical 
charts and the blood test results of all Korean GO patients 
who first visited both the departments of ophthalmology 
and endocrinology, Yonsei University College of Medicine 
from January 2008 to December 2011, were diagnosed 
with GO and Graves’ hyperthyroidism and had been 
followed up for ≥18 months. The patients were seen by 
both the endocrinologist and ophthalmologist in a 
combined clinic system for thyroid diseases. Thus the di-
agnoses of GD and GO were frequently made simultane-
ously. Initial diagnosis of GD was made by the department 
of endocrinology based on peripheral thyroid function, 
TRAb values, thyroid ultrasound pattern and/or thyroid 
scan, and clinical features such as diffuse goiter or 
hyperthyroidism symptoms. Initial diagnosis of GO was 
made based on clinical ophthalmic examination by one 
examiner (JSY) using the following assessments: history 
taking, slit-lamp examination, visual acuity, intraocular 
pressure, exophthalmometry measured with a Hertel 
exophthalmometer, Hess screen test, binocular single 
vision test, and a computed tomography scan.
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Among the 73 patients who visited both the department 
of ophthalmology and the department of endocrinology 
from January 2008 to December 2011, only patients with 
chronic inactive GO, restored euthyroidism, and simulta-
neous Mc4-TSI and third-generation M22-TBII assay mea-
surements were selected for analysis. One oculoplasty spe-
cialist (JSY) determined whether each patient was in the 
chronic inactive-stage of GO, through a thorough exam-
ination of each patient’s medial chart and photographs. In 
accordance with previous literature which reported that 
the average active inflammatory phase duration was ap-
proximately 18 months [2], we included only patients who 
had been diagnosed with GD or GO ≥18 months before en-
rollment. Patients with previous rehabilitative surgery such 
as orbital decompression and/or eyelid or muscle surgery 
were excluded. 
Laboratory data from the time point when the patient 
was determined to be in the chronic inactive-stage of GO 
was used for analysis. Thyroid function test (TSH and free 
T4 levels), which were measured with the TRAb assays 
were also analyzed. Only euthyroid patients with normal 
free T4 and TSH were included in the study. Past medical 
history, smoking history, GD and GO duration, current 
GD treatment type, family history of thyroid disease, and 
steroid use history were all recorded.
Clinical Graves’ orbitopathy evaluation
GO was diagnosed clinically using seven points of the 
clinical activity scores (CAS), as described by Mourits et 
al. [17] GO severity was assessed using the modified 
NOSPECS classification [18,19]. The modified NOSPECS 
score included the following: eyelid retraction (class 1), 
soft-tissue involvement (class 2), proptosis (class 3), 
extraocular muscle enlargement (class 4), and corneal (class 
5) or optic nerve (class 6) involvement. The individual 
class scores ranged from 0 to 3 (except for classes 1 and 2, 
which score a maximum of 2 points combined), according 
to severity, and the sum of the scores constituted the modi-
fied NOSPECS score (range, 0 to 14 points) [20].
Thyroid stimulating hormone receptor autoantibody 
assays
The M22-TBII (third-generation TRAb) assay was performed 
using the automated Cobas electrochemiluminescence im-
munoassay system (Elecsys; Roche Diagnostics, Penzberg, 
Germany). The cut-off value for positive results was 1.75 
IU/L. Mc4-TSI was measured with the Thyretain TSI 
reporter BioAssay (Diagnostic Hybrids, Athens, OH, USA) 
according to manufacturer instructions. Results were 
considered positive when the specimen-to-reference con-
trol ratio (SRR) was >140%. The antibody assays were 
performed at the same time as the physical examination 
and determination of CAS and NOPECS scores.
Statistical analysis
PASW Statistics ver. 18.0 (SPSS Inc., Chicago, IL, USA) 
was used to conduct data analyses. Spearman’s correlation 
coefficient was calculated to compare MC4-TSI and M22-
TBII to CAS scores, NOSPECS scores, and individual 
NOSPECS parameter scores. Regression analysis was used 
to evaluate the relationships between CAS, NOSPECS 
score, MC4-TSI level and M22-TBII levels, to reveal which 
of the laboratory parameters might correlate with disease 
activity or severity scores. Data were presented as means ± 
standard deviation, unless otherwise indicated.
Results
Fifty patients were included in the study. Their mean age 
was 41.3 ± 14.2 years, and 41 (82%) patients were women. 
The median GD duration was 62.7 months (range, 18 to 
401 months) and the median GO duration was 46.3 months 
(range, 18 to 240 months). 
Table 1 shows patient demographics and basic examina-
tion parameter data. The average exophthalmometery 
measurement was 18.1 ± 3.0 mm and the difference be-
tween right and left eyes was 0.7 ± 0.9 mm. The average 
TSH level was 2.27 ± 9.52 µIU/mL, free T4 was 1.57 ± 0.99 
ng/mL, and T3 was 4.2 ± 18.8 ng/mL. The average NO-
SPECS score was 4.8 ± 3.1 points and the average CAS 
score was 0.5 ± 0.9 points. Among the participants, 33 pa-
tients had a CAS score of 0 points, 9 patients had a CAS 
score of 1 point, 6 patients had a CAS score of 2 points, 
and 2 patients had a CAS score of 3 points. 
The mean Mc4-TSI level was 325.9 ± 210.1 SRR%, and 
the mean level of M22-TBII was 7.5 ± 10.2 IU/L. Seventy 
per cent of patients showed positive Mc4-TSI values (>140 
SRR%) and 62% of patients showed positive M22-TBII 
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values (>1.75 IU/L). Fifty-four percent of patients showed 
positive results in both TRAb assays (Table 1).
When MC4-TSI and M22-TBII results were compared 
with disease activity and severity scores, MC4-TSI levels 
correlated with NOSPECS score (R = 0.479, p < 0.001), but 
not with CAS (p = 0.250) (Fig. 1). On the other hand, M22-
TBII results did not correlate with either CAS (p = 0.053) 
or NOSPECS scores (p = 0.097) (Fig. 2). MC4-TSI levels 
did correlate with two individual NOSPECS parameters: 
extraocular muscle involvement (R = 0.412, p = 0.003) and 
soft tissue involvement (R = 0.325, p = 0.021). However, 
M22-TBII did not correlate with any of the NOSPECS pa-
rameters. With respect to the exophthalmometry value, 
neither MC4-TSI nor M22-TBII were significantly associ-
ated with NOSPECS parameters (p > 0.05 for both com-
parisons, Pearson’s correlation) (Table 2).
Univariate analysis of CAS values and NOSPECS scores 
with respect to both MC4-TSI and M22-TBII levels was 
Table 1. Patient demographics
Characteristics Value
Included study population (n) 50
Age (yr) 41.3 ± 14.2
Female sex 41 (82)
Duration of GD (mon, median [IQR]) 62.7 (31.8)
Duration of GO (mon, median [IQR]) 46.3 (33.8)
Duration of ATD (mon, median [IQR]) 50.2 (26.5)
Follow-up duration (mon, median 
[IQR])
29.1 (20.5)
Smokers 6 (12.0)
Diabetes mellitus 3 (6.0)
Hypertension 4 (8.0)
Family history of thyroid disease 6 (12.0)
Prior thyroid treat modalities 
ATD / RAI / surgery / none            
(% of patients)
98 / 4 / 6 / 0
TSH (0.35-4.94 µIU/mL ) 2.27 ± 9.52
Free T4 (0.70-1.48 ng/dL) 1.14 ± 0.20
T3 (0.58-1.59 ng/mL) 4.27 ± 18.78
Mc4-TSI, <140 SRR (%)
Mean ± SD 325.9 ± 210.1
Median (range) 265.15 (45.00-881.90)
Positive 35 (70)
M22-TBII (≥1.75 IU/L)
Mean ± SD 7.49 ± 10.15
Median (range) 2.80 (0.30-40.00)
Positive 31 (62)
Values are presented as mean ± SD or number (%) unless 
otherwise indicated.
GD = Graves’ disease; IQR = interquartile range; GO = Graves’ 
orbitopathy; ATD = anti-thyroid drug; RAI = radioiodine thera-
py; TSH = thyroid-stimulating hormone; TSI = thyroid-stimulat-
ing immunoglobulin; SRR = specimen-to-reference ratio; SD = 
standard deviation; TBII = thyrotropin-binding inhibitory immu-
noglobulin.
Mc
4-T
SI
 va
lue
Mc
4-T
SI
 va
lue
CAS score
R = 0.166
p = 0.250
1,000.0
800.0
600.0
400.0
200.0
0
0 1 2 3
NOSPECS score
R = 0.479
p < 0.001
1,000.0
800.0
600.0
400.0
200.0
0
0     1     2     3     4     5     6     7     8     9    10    11   12   13    14
Fig. 1. Comparison of Mc4 thyroid-stimulating immunoglobulin 
(TSI) value with disease activity and severity scores. Comparison 
with (A) clinical activity score (CAS) score and with (B) NO-
SPECS score. In these graphs, Mc4-TSI value showed no definite 
correlation with CAS score (p = 0.250), however Mc4-TSI value 
was correlated with NOSEPCS score (p < 0.001).
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conducted using a linear regression model, and only MC4-
TSI levels were significantly predictive of NOSPECS score 
(R2 = 0.164, p = 0.007).
Discussion
TRAb measurement is widely accepted as a routine 
method for diagnosing and monitoring Graves’ hyperthy-
roidism [18]. The TRAb assay technique has improved in 
diagnostic sensitivity and specificity for evaluating Graves’ 
hyperthyroidism. In the ophthalmology field, TSI has pro-
vided greater performance power for assessing GO clinical 
manifestations [10]. In recent years, Mc4-TSI has been 
correlated with the activity and severity of untreated GO 
in the early disease period [12,13]. In the present study, we 
focused on the relevance of TRAb in chronic-stage GO. 
Interestingly, data from 50 patients with chronic inac-
tive-stage GO showed that only Mc4-TSI, but not TBII, 
significantly correlated with the NOSPECS score. Neither 
TRAb levels correlated with CAS. 
The GO activity score, CAS, did not associate with the 
two TRAb assays in chronic inactive-stage GO. One possi-
ble explanation might be that the majority of included sub-
jects had low CAS scores. In this study, the mean CAS was 
0.5 and 84% of patients had CAS values of 0 to 1 (42 out of 
50 patients). These results were significantly different than 
a previous report that investigated the relationship between 
TRAb and disease activity in early untreated GO patients. 
Ponto et al. [13] emphasized a strikingly high correlation 
between Mc4-TSI levels and chemosis, which is a clinically 
important sign of the degree of acute inflammation. 
Mc4-TSI levels associated with NOSPECS scores, espe-
cially the myopathy parameter score. The high TSI level in 
some patients with severe clinical courses, even after 
inf lammatory activity had completely subsided, was an 
unexpected finding. Higher levels of TSI in the early stag-
Table 2. Correlation of NOPECS* score parameters with M22-
TBII and Mc4-TSI
Parameters of   
NOSPECS score
M22-TBII Mc4-TSI
R p-value R p-value
Eyelid retraction -0.042 0.770 -0.002 0.992
Soft-tissue involvement  0.136 0.347  0.325 0.021
Proptosis -0.067 0.637  0.261 0.068
Extraocular muscle
enlargement
 0.244 0.087  0.412 0.003
Corneal involvement  0.067 0.644  0.058 0.690
Optic nerve 
involvement
 0.245 0.086  0.150 0.299
Spearman’s correlation statistical method was used to compare 
each group. 
TBII = thyrotropin-binding inhibitory immunoglobulin; TSI = 
thyroid-stimulating immunoglobulin.
*Endocrine ophthalmology grading scheme proposed in 1969 by 
SC Werner.
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Fig. 2. Comparison of M22 thyrotropin-binding inhibitory im-
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immunoglobulin, M22-TBII was not correlated with any of dis-
ease activity (p = 0.053) or severity score (p = 0.097).
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es of GO indicated that patients had a more active and se-
vere disease, and therefore it follows that they would also 
have higher antibody levels and a more severe chronic in-
active stage of the disease. It is well known that TRAb lev-
els decrease with ATD use and/or over the natural disease 
course. Laurberg et al. [21] reported that the largest de-
crease in TRAb levels occurred within the first 6 months 
of ATD treatment. In the present study, the mean duration 
of Graves’ hyperthyroidism was 63 months and the mean 
duration of GO was 46 months. All patients had been 
treated previously with ATD for a median of 52.3 months. 
However, TRAb levels from the Mc4-TSI bioassay, but not 
the third-generation TBII, was still clinically relevant in 
reflecting disease severity even in chronic inactive GO. 
Since the pathogenesis of GO is not fully understood, it 
is difficult to explain why the TSI bioassay was superior 
over the TBII assay in reflecting GO severity scores, even 
in the chronic inactive disease stage. We recently investi-
gated the clinical characteristics of GO patients who 
showed discrepancies between TSI and TBII levels [22]. A 
certain patient group presenting with relatively high TSI 
but low TBII were found to also have high CAS and NO-
SPECS scores; however, patients with hyperthyroidism 
were more likely to present with high TBII but low TSI 
levels. Another study that compared the performance of 
first- and third-generation TBII and TSI bioassays showed 
that the Mc4-TSI bioassay was superior to the two TBIIs 
in assessing active inf lammation and muscle restriction 
due to GO [22]. Additionally, ethnic difference should be 
considered because Chng et al. [23] mentioned in their re-
view article that the TSI seemed to reflect GO status better 
than TBII, especially in Asian patients.
In some cases, we found that the CAS did not accurately 
reflect the status of a patient’s orbital inflammation, and 
high TSI levels were often associated with on-going 
autoimmune disease processes. However, patients with a 
high CAS sometimes did not have active inflammation, but 
showed congestive symptoms caused by interruption of 
venous outf low caused by elevated intraorbital pressure. 
Differentiating congestion and actual inflammation would 
help improve the medical management of GO. However, 
CAS is currently the only clear standard to define orbital 
inf lammation in GO. Generally, in a clinically setting, 
inf lammatory activity during GO is evaluated by CAS, 
and anti-inf lammatory treatment is initiated in patients 
with a high CAS. Our finding that TSI levels remained ele-
vated in some patients with a severe clinical GO course, 
even after inflammatory activity determined by CAS had 
completely disappeared, was unexpected. When evaluating 
and treating GO patients, both TSI and clinical parameters 
should be equally considered. The results of this study in-
dicate that rehabilitation surgery should not be delayed 
until negative conversion of TSI, because TSI is not a good 
marker for the clinically inactive disease state. 
Although the present study has a limitation inherent to 
its retrospective nature and small sample size, it is worth 
noting that Mc4-TSI was high in patients with high NO-
SPECS score, especially those with high myopathy param-
eter subscores, even in the chronic inactive stage of GO. 
We believe that serial follow-up of TSI levels might pro-
vide important clinical information to better evaluate and 
properly treat GO.
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